Skip to main content
OpenTrials
Completed

NCT Number: NCT06115031

Remimazolam vs. Propofol: Impact on Postoperative Delirium in Neurosurgical Patients

The investigator aimed to evaluate the incidence of postoperative delirium after remimazolam-based total intravenous anesthesia (TIVA) compared to the propofol-based TIVA in patients undergoing neurosurgery.

Completed

Looking for future studies?

Notify Me

Key information

Age range

19 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Samsung Medical Center

Seoul, 06351, South Korea

About this study

Remimazolam, a short-acting benzodiazepine, has recently gained approval for use in the induction and maintenance of general anesthesia. In American Society of Anesthesiologists (ASA) physical status class I and II patients undergoing general anesthesia, the remimazolam-based TIVA has shown comparable efficacy to propofol-based TIVA while demonstrating a superior safety profile. Remimazolam has exhibited a lower incidence of hypotension, reduced vasopressor requirements, and fewer instances of bradycardia compared to the propofol-based TIVA.

The use of benzodiazepine has been associated with an increased risk of postoperative delirium, but there is currently no randomized controlled trial investigating the relationship between remimazolam, a new short-acting benzodiazepine, and postoperative delirium. Therefore, the investigators designed this prospective, randomized, double-blinded, active comparator-controlled, non-inferiority trial to investigate the incidence of postoperative delirium after remimazolam-based TIVA compared with propofol-based TIVA in neurosurgery patients.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • American Society of Anesthesiologists (ASA) physical status class I - III

Exclusion criteria

  • Severe respiratory, cardiovascular, or hepatic disease (Child-Pugh C)
  • Dependency on psychiatric drugs or alcohol
  • Severe sensory impairments that impede communication
  • Preoperative delirium
  • Hypersensitivity, allergies, or contraindication to the study drugs.

Treatment and study plan

Remimazolam

Drug

General anesthesia will be induced and maintained using continuous infusion of intravenous remimazolam.

Other names: byfavo inj

Propofol

Drug

General anesthesia will be induced and maintained using target-controlled infusion of intravenous propofol.

Other names: Fresofol

Primary outcomes

  1. Postoperative delirium

    Time frame: assessed up to postoperative day 5 or patient discharge, whichever came first

    The occurrence of postoperative delirium, defined as at least one positive assessment during the postoperative period. Delirium will be assessed twice a day using confusion assessment method for the intensive care unit (CAM-ICU) and 3-minute diagnostic assessment for CAM-defined delirium (3D-CAM).

    These are binary diagnostic instruments (delirium present vs absent), not scored scales.

Secondary outcomes

  1. Duration of postoperative delirium

    Time frame: from the end of surgery to the postoperative day 5

    Duration is quantified as the cumulative number of positive CAM-ICU or 3D-CAM assessments (protocol secondary outcome: number of positive delirium assessment) collected twice daily.

  2. Delirium subtypes

    Time frame: assessed twice a day up to postoperative day 5 or patient discharge, whichever came first

    Hypoactive/hyperactive/mixed

  3. Severity of postoperative delirium

    Time frame: assessed twice a day up to postoperative day 5 or patient discharge, whichever came first

    Severity of postoperative delirium will be assessed twice a day using DRS-R-98 (delirium rating scale-revised-98); total score range 0-46; higher scores = more severe delirium.

  4. Emergence agitation

    Time frame: within 30 min after extubation

    Incidence of emergence agitation, defined as Richmond Agitation-Sedation Scale (RASS) ≥+1 within 30 minutes after extubation. RASS ranges from -5 to +4; higher scores indicate greater agitation. The outcome is binary (emergence agitation present vs absent).

  5. delayed extubation

    Time frame: Up to 1 hour after surgery

    Percentage of the patients who were not extubated in the OR and transferred to the ICU, delayed extubation (> 1 h after surgery completion)

  6. Intraoperative awareness

    Time frame: at postoperative day 0

    Intraoperative awareness will be assessed using Modified Brice questionnaire; binary outcome, not a scored scale.

  7. Undesirable patient movement

    Time frame: During surgery

    Undesirable movement of patient during surgery

  8. Intraoperative adverse events

    Time frame: During surgery

    bradycardia with the use of chronotropic agent, laryngeal spasm, bronchospasm, allergic reaction, arrhythmia, cardiac events (myocardial infarction, vasospasm, or cardiac arrest), or massive bleeding

  9. Intraoperative hypotension

    Time frame: During surgery

    Intraoperative hypotension, quantified as the area under the mean arterial pressure threshold of 65 mm Hg. (Unit: mm Hg·min)

  10. Quality of early recovery

    Time frame: postoperative day 1

    Quality of Recovery-15 (QoR-15); score range 0-150; higher = better recovery.

  11. Postoperative complication

    Time frame: Up to 30 days after surgery

    assessed by Clavien-Dindo classification Data are presented as the proportion of patients with 1 or more events (edema, vasospasm, rebleeding, seizures, and/or ischemia, etc.)

  12. Length of stay in ICU after surgery

    Time frame: from the day of surgery to the time of patient discharge from ICU, assessed up to 3 months after surgery

    days

  13. Length of stay in hospital after surgery

    Time frame: from the day of surgery to the time of patient discharge, assessed up to 3 months after surgery

    days

  14. Fall

    Time frame: 3-months after surgery

    the incidence of postoperative falls and associated injury (presence of fracture)

  15. Postoperative cognitive dysfunction

    Time frame: postoperative day 7, 3-months after surgery

    Changes in cognition assessed by Montreal Cognitive Assessment (MoCA) at baseline and postoperative day 7 (or discharge, whichever comes first); range 0-30; higher = better cognition. And by telephone-MoCA (T-MoCA) at 3 months;range 0-22; higher = better cognition.

  16. Functional status

    Time frame: 3-months after surgery

    assessed using Barthel activity of daily living (ADL) index

    ; score range 0-20; higher = greater independence.

Other outcomes

  1. Incidence of postoperative nausea and vomiting (PONV)

    Time frame: Up to 3 days (72 hours) after surgery

    PONV sub-study is a pre-planned non-inferiority sub-study for this main trial. Number (percentage) of participants with nausea and/or vomiting, assessed in participants enrolled in the PONV sub-study.

  2. Severity of postoperative nausea and vomiting (PONV)

    Time frame: Up to 3 days (72 hours) after surgery

    Severity of postoperative nausea and vomiting, assessed using the PONV Intensity Scale in participants enrolled in the PONV sub-study. Higher scores indicate more severe PONV.

  3. Rescue anti-emetic administration

    Time frame: Up to 3 days (72 hours) after surgery

    Number (percentage) of participants who received rescue anti-emetic medication in the PONV sub-study.

  4. Subgroup analysis of delirium incidence assessed by CAM-ICU or 3D-CAM

    Time frame: assessed up to postoperative day 5 or patient discharge, whichever came first

    Subgroup analysis (age, sex, surgery type, preoperative cognitive impairment, ASA physical status, duration of anesthesia, alcohol abuse, or chronic benzodiazepine use)

  5. Intraoperative EEG spectral power

    Time frame: During surgery

    Relative spectral power in the alpha, beta, delta, and theta frequency bands, derived from intraoperative electroencephalography (EEG).

  6. Intraoperative EEG phase-amplitude coupling

    Time frame: During surgery

    Phase-amplitude coupling between EEG frequency bands, derived from intraoperative EEG.

Sponsors and collaborators

Lead sponsor

Samsung Medical Center

Other

Registry information

Official study title

Effect of Remimazolam Versus Propofol Anesthesia on Postoperative Delirium in Neurosurgical Patients: A Randomised, Controlled, Noninferiority Trial

Important dates

Study start
2023
Primary completion
2025
Study completion
2026
First posted
Nov 2, 2023
Registry last updated
Jun 30, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.